FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology and immuno-oncology, in particular, to a bispecific binding protein binding to PD-1 and CTLA-4. The protein comprises a first heavy chain including CDR1 - GFTFSDYGMH, CDR2 - YISSGSYTIYSADSVKG, CDR3 - RAPNSFYEYYFDY; a first light chain including CDR1 - SASSKHTNLYWSRHMYWY, CDR2 - LTSNRAT, CDR3 - QQWSSNP; a second heavy chain including CDR1 - GFTFSSYGMH, CDR2 - VIWYDGSNKYYADSVKG, CDR3 - DPRGATLYYYYYGMDV; and a second light chain including CDR1 - RASQSINSYLD, CDR2 - AASSLQS, CDR3 - QQYYSTP. Also proposed are a composition containing such a protein, a nucleic acid molecule encoding the protein, a host cell for expression thereof, a method for treating or preventing cancer in a subject, and a method for increasing the immune response in a subject with cancer or subjected to a risk of developing cancer.
EFFECT: invention allows for production of bispecific binding proteins with improved binding properties relative to the initial monospecific binding proteins targeting the same molecules, even if used in combination.
12 cl, 90 dwg, 22 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
COMBINATION | 2015 |
|
RU2744841C2 |
MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
IMMUNOGLOBULIN WITH TANDEM ARRANGEMENT OF FAB FRAGMENTS AND APPLICATION THEREOF | 2014 |
|
RU2769133C2 |
MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
Authors
Dates
2022-02-09—Published
2017-05-05—Filed